Lonza Group AG (LZAGF)
Summary
LZAGF Chart
Lonza Group AG (LZAGF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lonza Group AG ever had a stock split?
Lonza Group AG Profile
| Professional Services Industry | Industrials Sector | Wolfgang Wienand CEO | OTC PINK Exchange | CH0013841017 ISIN |
| CH Country | 17,995 Employees | 12 May 2026 Last Dividend | 2 May 2017 Last Split | - IPO Date |
Overview
Lonza Group AG is a global leader in providing a wide array of products and services across the pharmaceutical, biotech, and nutrition markets. With a rich history dating back to 1897, Lonza has established a substantial presence across Europe, North and Central America, Latin America, Asia, Australia, and New Zealand. Its operations are categorized into four main segments: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Each of these segments plays a crucial role in Lonza’s efforts to support the healthcare and nutritional industries, ensuring that the company remains at the forefront of contract development and manufacturing services. Headquartered in Basel, Switzerland, Lonza is committed to driving innovation and excellence in the life sciences and nutrition sectors worldwide.
Products and Services
- Biologics
- Small Molecules
- Cell & Gene
- Capsules & Health Ingredients
Lonza’s Biologics segment specializes in the contract development and manufacturing of biopharmaceuticals, covering both clinical and commercial manufacturing needs across the entire product lifecycle. This includes both drug substance and drug product manufacturing, catering to a wide range of biopharmaceutical companies seeking reliable and comprehensive manufacturing solutions.
As an integrated service provider, the Small Molecules segment supports the development and manufacturing of small molecule drug substances and their intermediates. Lonza offers services across design, development, and manufacturing, which include particle engineering and drug product packaging. This segment addresses the needs of customers looking for end-to-end solutions in small molecule drug development.
This segment is dedicated to developing technologies and platforms that standardize the production processes of cell and gene therapies. It offers contract development and manufacturing services along with regulatory support for a variety of cell therapies (both allogeneic and autologous) and viral vector gene therapies. Key offerings also include the Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing, and specialty raw materials for the biomanufacturing market.
Lonza’s Capsules & Health Ingredients segment caters to pharmaceutical and nutraceutical customers, offering capsules, dosage form solutions, and health ingredients. This segment leverages Lonza’s expertise in capsule technologies and nutritional ingredients to support the development and delivery of effective health and wellness products.
